throbber
Docket No.: CGR5001USCNT1
`
`I hereby certifY that this correspondence is being transmitted via The Office
`
`Electronic Filing System (EFS) in accordance with 37 CFR l.6(a)(4).
`
`Date of Electronic (EFS) Transmission:
`
`December 21. 20 ll
`
`Signature: /Laurie A. Phillips/ Name: Laurie A. Phillips
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Application of:
`
`Applicant(s ):
`
`Title:
`
`Methods and Compositions for Treating Cancer
`
`Mail Stop Amendment
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-14 50
`
`RESPONSE TO RESTRICTION REQUIREMENT
`
`Dear Sir:
`
`The Office has issued a two-way restriction requirement relating to the present
`
`invention. Applicants hereby elect the invention of Group I, represented by newly
`
`presented claims 37 et seq. This election is made without traverse.
`
`Page 1 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 1
`
`

`
`Docket No.: CGR5001USCNT1
`
`Listing of Claims:
`
`1-36. (Canceled).
`
`37. (New) A method for the treatment of a prostate cancer m a human comprising
`
`administering to said human a therapeutically effective amount of abiraterone acetate or a
`
`pharmaceutically acceptable salt thereof and a therapeutically effective amount of
`
`prednisone.
`
`38. (New) The method of claim 37, wherein the therapeutically effective amount of the
`
`abiraterone acetate or pharmaceutically acceptable salt thereof is from about 50 mg/day
`
`to about 2000 mg/day.
`
`39. (New) The method of claim 38, wherein the therapeutically effective amount of the
`
`abiraterone acetate or pharmaceutically acceptable salt thereof is from about 500 mg/day
`
`to about 1500 mg/day.
`
`40. (New) The method of claim 39, wherein the therapeutically effective amount of the
`
`abiraterone acetate or pharmaceutically acceptable salt thereof is about 1000 mg/day.
`
`41. (New) The method of claim 37, wherein the therapeutically effective amount of the
`
`abiraterone acetate or a pharmaceutically acceptable salt thereof is administered in at
`
`Page 2 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 2
`
`

`
`Docket No.: CGR5001USCNT1
`
`least one dosage form compnsmg about 250 mg of abiraterone acetate or a
`
`pharmaceutically acceptable salt thereof.
`
`42. (New) The method of claim 37, wherein the therapeutically effective amount of the
`
`prednisone is from about 0.01 mg/day to about 500 mg/day.
`
`43. (New) The method of claim 42, wherein the therapeutically effective amount of the
`
`prednisone is from about 10 mg/day to about 250 mg/day.
`
`44. (New) The method of claim 44, wherein the therapeutically effective amount of the
`
`prednisone is about 10 mg/day.
`
`45. (New) The method of claim 37, wherein the therapeutically effective amount of the
`
`prednisone is administered in at least one dosage form comprising about 5 mg of
`
`prednisone.
`
`46. (New) The method of claim 37, comprising administering to said human about 500
`
`mg/day to about 1500 mg/day of abiraterone acetate or a pharmaceutically acceptable salt
`
`thereof and about 0.01 mg/day to about 500 mg/day of prednisone.
`
`47. (New) The method of claim 46, comprising administering to said human about 1000
`
`mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10
`
`mg/day of prednisone.
`
`Page 3 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 3
`
`

`
`Docket No.: CGR5001USCNT1
`
`48. (New) The method of claim 37, wherein said prostate cancer is refractory prostate
`
`cancer.
`
`49.
`
`(New) The method of claim 48, wherein the refractory prostate cancer IS not
`
`responding to at least one anti-cancer agent.
`
`50. (New) The method of claim 49, wherein the at least one anti-cancer agent comprises a
`
`hormonal ablation agent, an anti-androgen agent, or an anti-neoplastic agent.
`
`51. (New) The method of claim 50, wherein the hormonal ablation agent comprises
`
`deslorelin, leuprolide, goserelin, or triptorelin.
`
`52. (New) The method of claim 50, wherein the anti-androgen agent compnses
`
`bicalutamide, flutamide, or nilutamide.
`
`53. (New) The method of claim 50, wherein the anti-neoplastic agent compnses
`
`docetaxel.
`
`54. (New) The method of claim 48, comprising administering to said human about 500
`
`mg/day to about 1500 mg/day of abiraterone acetate or a pharmaceutically acceptable salt
`
`thereof and about 0.01 mg/day to about 500 mg/day of prednisone.
`
`Page 4 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 4
`
`

`
`Docket No.: CGR5001USCNT1
`
`55. (New) The method of claim 54, comprising administering to said human about 1000
`
`mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10
`
`mg/day of prednisone.
`
`56. (New) The method of claim 53, comprising administering to said human about 1000
`
`mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10
`
`mg/day of prednisone.
`
`Page 5 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 5
`
`

`
`Docket No.: CGR5001USCNT1
`
`Applicants respectfully request that a timely Notice of Allowance be issued in the
`
`present application. Should the office require anything further, it is invited to contact
`
`applicants' representative at the telephone number below.
`
`JOHNSON & JOHNSON
`One Johnson & Johnson Plaza
`New Brunswick, NJ 08933-7003
`(732) 524-3957
`Dated: December 21, 2011
`Customer No.: 27777
`
`Respectfully submitted,
`
`By: I Andrea Jo Kamage I
`Andrea Jo Kamage
`Reg. No. 43,703
`
`Page 6 of6
`
`MYLAN PHARMS. INC. EXHIBIT 1069 PAGE 6

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket